NCT03671044: A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

NCT03671044
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 65 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients may have received 1 prior chemotherapy regimen for adjuvant therapy and/or 1 chemotherapy treatment/regimen for 1st line metastatic therapy
Exclusions: Patients with known CNS lesions (brain metastasis or carcinomatous meningitis) except for asymptomatic brain metastases
https://ClinicalTrials.gov/show/NCT03671044

Comments are closed.

Up ↑